Abbott Laboratories sued Johnson & Johnson's Centocor unit over an alleged patent infringement. Centocor‘s Simponi (golimumab) would compete with Abbott's Humira, a rheumatoid arthritis treatment and the company's best selling drug – at $4.5 billion in global sales for 2008 – according to a Bloomberg report. Centocor's Simponi will be marketing by Schering-Plough outside of the US.
AstraZeneca filed a supplemental new drug application (sNDA) with the FDA for an expanded indication on Nexium. The new indication is for gastric and duodenal ulcers stemming from low-dose aspirin use. Nexium, a heartburn drug, is currently indicated for the treatment of acid reflux disease, as well as for risk reduction in the occurrence of gastric ulcers associated with continuous non-steroidal anti-inflammatory drug therapy.